



Pacific Center for
Emerging Infectious Diseases
Research



UNIVERSITY
of HAWAII
MĀNOA

COBRE/DEPT. OF TROPICAL MEDICINE SEMINAR

Clinical and Preclinical Development of a Recombinant Subunit Vaccine for Dengue

Beth-Ann Griswald Coller, Ph.D.

*Executive Director, Global Clinical Development
Merck & Co., Inc.
North Wales, Pennsylvania*

Dr. Beth-Ann Coller Ph.D., Executive Director with Merck and Co., and former Senior Vice President for Research and Development at Hawaii Biotech, Inc., will present an overview of the most recent clinical and preclinical results for the Hawaii Biotech/Merck dengue vaccine candidate. Dr. Coller received her Ph.D. in 1993 from the University of Nebraska Medical Center, where she studied the molecular virology of picornaviruses. She then joined Hawaii Biotech where her research focused on development of recombinant subunit flavivirus vaccines. In 1999, Dr. Coller joined GlaxoSmithKline Biologicals in Rixensart Belgium where she was the project manager for the dengue vaccine project and led the Preclinical Virology Group which was responsible for preclinical development of all viral vaccine projects. In 2004 Dr. Coller rejoined Hawaii Biotech and was ultimately responsible for all Research and Development activities including the development of the HBI West Nile and dengue vaccines. In August 2010, with the Merck acquisition of the Hawaii Biotech dengue program, Dr. Coller joined Merck where she is currently leading the product development teams for dengue and other vaccine targets.

Wednesday, January 7, 2015 at 12:00 noon
John A. Burns School of Medicine, Kaka'ako
Medical Education Building Auditorium (Room 315)
For further information, contact (808) 692-1654

The Center and its activities are supported by a grant (P20GM103516) from the National Institute of General Medical Sciences, National Institutes of Health.

